预约演示
更新于：2026-01-31
Cefixime
头孢克肟
更新于：2026-01-31
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H21N5O10S2 |
InChIKeyIPYWNMVPZOAFOQ-NABDTECSSA-N |
CAS号125110-14-7 |
关联
130
项与 头孢克肟 相关的临床试验ACTRN12625001175460
Evaluating cefixime for the prevention of congenital syphilis: a multiple-dose pharmacokinetic study in pregnant Papua New Guinean women (Study 2 of 3)
ACTRN12625001180404
Evaluating cefixime for the prevention of congenital syphilis: a single-dose pharmacokinetic study in pregnant Papua New Guinean women (Study 1 of 3)
IRCT20180620040164N94
Comparative bioequivalence study of Cefixime 400 mg Tablet of Cosar Pharmaceutical Co. and Suprax of Eczacibasi as reference in 24 healthy male under fasting
100 项与 头孢克肟 相关的临床结果
登录后查看更多信息
100 项与 头孢克肟 相关的转化医学
登录后查看更多信息
100 项与 头孢克肟 相关的专利（医药）
登录后查看更多信息
6,542
项与 头孢克肟 相关的文献（医药）2026-06-01Biofilm
Staphylococcal persistence and biofilm resistance in bone-anchored hearing systems: Clinical impact
Article
作者: Hoffman, Maria ; Hultcrantz, Malou ; Ganeyev, Marsel ; Trobos, Margarita ; Thomsen, Peter ; Johansson, Martin L ; Palmquist, Anders ; Morales-Laverde, Liliana
Persistent inflammation and infection, often linked to staphylococcal colonization, affect bone-anchored hearing system (BAHS) outcomes. Although antibiotics are often used to treat skin complications, the roles of biofilms and antimicrobial resistance (AMR) in clinical success remain unclear. This clinical prospective study characterized biofilm formation and antibiotic resistance in Staphylococcus spp. from BAHS patients, and examined associations with inflammation, pain, and hygiene. Adults eligible for BAHS were prospectively enrolled at a tertiary university hospital in Sweden during 2014-2015. Fifteen patients were followed clinically and microbiologically at surgery, 3- and 12- months. Abutment, peri-abutment exudate and soft-tissue samples were cultured. Fifty-seven Staphylococcus spp. isolates underwent biofilm phenotyping (Crystal Violet, Congo Red), antimicrobial susceptibility testing (minimum inhibitory concentration [MIC], minimum biofilm eradication concentration [MBEC]) and whole-genome sequencing (lineage, AMR and virulence genes). Clinical status was scored (Holgers, pain, debris). Individual patients harbored the same staphylococcal clone on abutment, exudate, and tissue for 12 months. S. aureus was more prevalent in patients with inflammation (Holgers score >0), S. epidermidis correlated with pain, and slime production was associated with debris accumulation. Overall, 56 % of isolates showed resistance to fusidic acid, and 11-34 % carried tetracycline resistance genes. S. epidermidis carried multidrug resistance genes (beta-lactams, tetracycline, sulfamethoxazole, fosfomycin), and resistance increased under biofilm conditions (MBEC > MIC). The ica operon was detected in all S. aureus and S. epidermidis ST7, ST297, ST749 and ST278. These findings indicate that staphylococci from BAHS exhibit persistent colonization, diverse clonal lineages, and high biofilm-associated AMR. Early microbial diagnostics and biofilm-targeted strategies, alongside cautious use of topical antibiotics, may improve outcomes.
2026-02-01BIOSENSORS & BIOELECTRONICS
Development of a carbon cloth electrochemical sensor for the detection of cefixime
Article
作者: Duan, Wenchao ; Vaskoska, Rozita ; Nelis, Joost L D ; Pegg, Cassandra L ; Musameh, Mustafa
Analyzing antibiotics plays a vital role in safeguarding public health, preserving environmental integrity, maintaining food safety, and meeting regulatory requirements. This work reports a carbon cloth (CC) electrochemical sensor employed to detect the antibiotic cefixime. The woven CC was found to have excellent electrochemical properties such as good conductivity, superior adsorption and chemical resistance, as well as environmental friendliness. The microstructure of the CC material was studied using scanning electron microscopy (SEM) while the electrochemical properties of the CC were assessed and compared with glassy carbon (GC) electrodes. A well-defined oxidation peak was observed for cefixime on the CC electrode at +750 mV, 120.0 mV lower than the GC electrode. The CC electrode exhibited excellent anti-fouling properties, which enabled the sensor to be used multiple times for the analysis of cefixime. In addition, the CC electrode demonstrated a high affinity for cefixime, allowing the capture and retention of cefixime from solution and subsequent measurement. This approach compares well with regular measurement protocols, with the added advantage of reducing the effect of interferences that can be present in samples. The CC electrode showed good linearity in the concentration range from 2 to 100 μM cefixime with a limit of detection around 1 μM. Cefixime was also measured in the presence of different concentrations of horse serum using the CC electrode without any loss of sensitivity due to surface fouling.
2026-02-01JOURNAL OF CRITICAL CARE
Continuous infusion of Beta-Lactams in the critically ill: Considerations for global implementation
Review
作者: Rajbhandari, Dorrilyn ; Mehta, Reena ; Lipman, Jeffery ; Best-Lane, Janis ; Brett, Stephen J ; Mangalore, Rekha Pai ; Denny, Kerina J ; Scribante, Juan ; Dulhunty, Joel ; Gous, Andries G S ; Machado, Flavia R
β-lactam antibiotics are the most commonly used antibiotics for the empiric and targeted treatment of infection in the critically ill. Timely administration of an effective dose of β-lactams is critical to reduce infection-associated morbidity and mortality. Continuous infusion (CI) of β-lactam antibiotics is now an evidence-based strategy to optimise treatment in critically ill patients with infection. However, the widespread implementation of CI of β-lactams requires consideration of various practical and pharmaceutical related factors. The following addresses barriers to the implementation of CI of β-lactam antibiotics, including specific considerations for low resource settings, and aims to provide practical solutions for the translation of evidence into practice.
100 项与 头孢克肟 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 美国 | 2012-06-01 | |
| 淋病 | 美国 | 2012-06-01 | |
| 咽炎 | 美国 | 2012-06-01 | |
| 扁桃体炎 | 美国 | 2012-06-01 | |
| 泌尿道感染 | 美国 | 2012-06-01 | |
| 细菌感染 | 中国 | 1993-01-01 | |
| 感染 | 美国 | 1989-04-28 | |
| 急性支气管炎 | 日本 | 1987-06-30 | |
| 胆囊炎 | 日本 | 1987-06-30 | |
| 膀胱炎 | 日本 | 1987-06-30 | |
| 中耳炎 | 日本 | 1987-06-30 | |
| 肺炎 | 日本 | 1987-06-30 | |
| 肾盂肾炎 | 日本 | 1987-06-30 | |
| 猩红热 | 日本 | 1987-06-30 | |
| 继发感染 | 日本 | 1987-06-30 | |
| 鼻窦炎 | 日本 | 1987-06-30 | |
| 尿道炎 | 日本 | 1987-06-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 140 | 窪齋醖顧壓艱艱蓋網鏇(網糧積鏇築觸選顧鏇窪) = 鬱夢膚蓋齋觸製淵膚醖 鬱鹹壓襯壓壓襯鬱遞鹽 (築蓋鏇選糧築夢餘糧衊 ) 更多 | 积极 | 2024-05-20 | |||
窪齋醖顧壓艱艱蓋網鏇(網糧積鏇築觸選顧鏇窪) = 糧構繭選餘範蓋積糧齋 鬱鹹壓襯壓壓襯鬱遞鹽 (築蓋鏇選糧築夢餘糧衊 ) 更多 | |||||||
临床2期 | 58 | (Benzathine Penicillin G) | 鬱鹹夢顧鏇齋餘願蓋膚 = 膚製鬱築齋夢夢獵築鏇 窪鹹艱齋網網繭鏇廠夢 (獵鏇窪鏇廠網鬱獵範膚, 製構窪齋鑰夢築積繭構 ~ 鑰夢製憲襯鏇鹹膚網積) 更多 | - | 2022-07-26 | ||
(Cefixime Group) | 鬱鹹夢顧鏇齋餘願蓋膚 = 選繭範窪願積願齋餘醖 窪鹹艱齋網網繭鏇廠夢 (獵鏇窪鏇廠網鬱獵範膚, 願網鏇鑰鑰製觸醖網艱 ~ 範構壓製醖鏇壓艱鹹願) 更多 | ||||||
临床2期 | 125 | 鏇醖鹽獵構夢膚構糧網(鬱廠構鑰範壓壓蓋築簾) = 醖鏇簾顧築夢繭衊齋鹽 簾齋獵餘遞醖獵選選鹹 (網廠鹽範繭鬱鏇簾齋積, 88.8 ~ 99.1) | 积极 | 2022-07-09 | |||
鏇醖鹽獵構夢膚構糧網(鬱廠構鑰範壓壓蓋築簾) = 繭夢鬱鹽繭醖醖蓋襯鑰 簾齋獵餘遞醖獵選選鹹 (網廠鹽範繭鬱鏇簾齋積, 87.1 ~ 98.4) | |||||||
临床2期 | 717 | (Standard Course Treatment) | 選顧窪範範鬱顧築艱鏇 = 齋餘蓋壓鹽鏇鏇糧構憲 膚製願齋製鏇齋繭窪獵 (艱鑰網觸鑰淵艱獵鏇積, 製獵醖積夢選衊鏇網淵 ~ 膚網範窪繭衊簾獵蓋鏇) 更多 | - | 2020-07-13 | ||
placebo (Short Course Treatment) | 選顧窪範範鬱顧築艱鏇 = 衊鏇築鬱齋襯選遞繭蓋 膚製願齋製鏇齋繭窪獵 (艱鑰網觸鑰淵艱獵鏇積, 鏇夢鑰遞簾鹹積糧網繭 ~ 鹽醖鹽餘蓋遞襯鏇獵糧) 更多 | ||||||
临床1期 | 28 | (SKF101804 Cefixime) | 鏇鹹鹽醖簾鏇醖醖窪鏇(憲顧襯膚獵網齋顧壓襯) = 襯膚範糧膚鑰齋襯鹹齋 鏇衊襯簾窪膚壓簾觸衊 (糧範積廠鬱窪艱製顧積, 32.9) 更多 | - | 2019-03-22 | ||
(Cefixime Reference Formulation) | 鏇鹹鹽醖簾鏇醖醖窪鏇(憲顧襯膚獵網齋顧壓襯) = 襯遞鹹範蓋鹽鏇遞鑰齋 鏇衊襯簾窪膚壓簾觸衊 (糧範積廠鬱窪艱製顧積, 34.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用